Core Insights - BioAge Labs is advancing its clinical pipeline with the oral NLRP3 inhibitor BGE-102, set to initiate Phase 1 trials in the second half of 2025, with initial data expected by year-end [2][3] - The company has expanded its APJ agonist pipeline through a partnership for potent antibodies and has filed patents for novel oral small molecules [2][7] - BioAge is enhancing its discovery platform by profiling over 17,000 samples from the HUNT Biobank, which will generate millions of data points related to human longevity [5] Clinical Pipeline Development - The BGE-102 program has completed IND-enabling studies and has shown significant weight loss in preclinical models, both as a standalone treatment and in combination with semaglutide [3] - The Phase 1 SAD/MAD clinical trial for BGE-102 is planned for the second half of 2025, with initial SAD data anticipated by the end of the year [3][13] APJ Agonist Pipeline Expansion - BioAge entered an exclusive option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody, which is reported to have over 10-fold greater potency than apelin [7] - The company has filed a U.S. provisional patent for a new class of orally active APJ agonists with high solubility and metabolic stability [7] Discovery Platform Expansion - BioAge's collaboration with the HUNT Biobank aims to profile over 17,000 samples from more than 6,000 participants, generating extensive molecular measurements over decades [5] - The partnership provides BioAge exclusive access to the data for drug discovery purposes [5] Financial Performance - For Q2 2025, research and development expenses were $19.8 million, up from $10.5 million in Q2 2024, primarily due to increased costs related to licensing and development activities [9] - General and administrative expenses rose to $7.3 million from $4.8 million in the same period last year, driven by higher personnel-related expenses [10] - The net loss for Q2 2025 was $21.6 million, or $0.60 per share, compared to a net loss of $13.6 million, or $7.94 per share, in Q2 2024 [11] Cash Position - As of June 30, 2025, BioAge had approximately $313.4 million in cash, cash equivalents, and marketable securities, which is expected to fund operations through 2029 [12]
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates